PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)
PARP Inhibitor Biomarkers Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
»óǰÄÚµå
:
1701659
¸®¼Ä¡»ç
:
Persistence Market Research
¹ßÇàÀÏ
:
2025³â 04¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 180 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
ÁÖ¿ä Á¶»ç °á°ú
PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð : 10¾ï 3,530¸¸ ´Þ·¯(2025³â)
¿¹»ó ½ÃÀå ±Ô¸ð : 18¾ï 3,340¸¸ ´Þ·¯(2032³â)
¼¼°è ½ÃÀå ¼ºÀå·ü : 8.5%(2025-2032³â CAGR)
PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå - º¸°í¼ ¹üÀ§
PARP(Æú¸® ADP ¸®º¸½º ÁßÇÕÈ¿¼Ò) ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿´Â PARP ¾ïÁ¦Á¦ Ä¡·áÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö Àִ ȯÀÚ¸¦ ½Äº°ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, ƯÈ÷ Á¾¾ç ºÐ¾ß¿¡¼ Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¸¶Ä¿¿¡´Â BRCA1/2 µ¹¿¬º¯ÀÌ, »óµ¿ ÀçÁ¶ÇÕ º¹±¸ °á¼Õ(HRD), ±âŸ DNA ¼Õ»ó ¹ÝÀÀ(DDR) °æ·ÎÀÇ º¯È°¡ Æ÷ÇԵ˴ϴÙ. ½ÃÀåÀº ƯÈ÷ ³¼Ò¾Ï, À¯¹æ¾Ï, Àü¸³¼±¾Ï, ÃéÀå¾Ï µîÀÇ Ä¡·á¿¡ ÀÖ¾î ÀÓ»óÀǸ¦ Áö¿øÇÔÀ¸·Î½á Á¤¹Ð Á¾¾çÇÐ Áø·á¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý Ä¡·á Á¢±Ù¹ýÀÇ Ã¤ÅÃÀÌ °¡¼Óȵǰí ÀÖ½À´Ï´Ù. À¯Àüü ÇÁ·ÎÆÄÀϸµ, Â÷¼¼´ë ¿°±â¼¿ ºÐ¼®(NGS), µ¿¹ÝÁø´ÜÀÇ ¹ßÀüÀÌ ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
¼¼°è PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº ¾Ï ¹ßº´·ü Áõ°¡¿Í Ç¥ÀûÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖÀ¸¸ç, PARP ¾ïÁ¦Á¦°¡ ¿©·¯ ¾Ï¿¡ ´ëÇÑ Ä¡·áÁ¦·Î ½ÂÀεʿ¡ µû¶ó ¹ÙÀÌ¿À¸¶Ä¿ »óŸ¦ ±â¹ÝÀ¸·Î Àû°Ý ȯÀÚ¸¦ ½Äº°ÇÏ´Â µ¿¹ÝÁø´Ü °Ë»ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. PARP ¾ïÁ¦Á¦¿¡ ´ëÇÑ ¹ÝÀÀ¼º ¿¹ÃøÀÎÀÚ·Î BRCA À¯ÀüÀÚ º¯ÀÌ ¹× HRD¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¹ÙÀÌ¿À¸¶Ä¿ °Ë»çÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯Áö¿ä¹ý ¹× º´¿ë¿ä¹ý¿¡¼ PARP ¾ïÁ¦Á¦ÀÇ »ç¿ëÀÌ È®´ëµÇ¸é¼ ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤¹Ð Á¾¾çÇп¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø°ú À¯Àüü ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ È®´ëµµ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¾ïÁ¦¿äÀÎ
PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº Å« ¼ºÀå ÀáÀç·Â¿¡µµ ºÒ±¸ÇÏ°í ¿©·¯ °¡Áö Á¦¾à¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç ¹× Â÷¼¼´ë ¿°±â¼¿ ºÐ¼® ±â¼ú°ú °ü·ÃµÈ ³ôÀº ºñ¿ë, ƯÈ÷ ÁßÀú¼Òµæ Áö¿ª¿¡¼´Â ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. µ¿¹ÝÁø´Ü ¾àǰ¿¡ ´ëÇÑ »óȯ Àå¾Ö¹°°ú º¹ÀâÇÑ ±ÔÁ¦´Â »õ·Î¿î °Ë»çÀÇ ½ÃÀå ÁøÀÔÀ» Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, PARP ¾ïÁ¦Á¦ÀÇ Àû°Ý¼ºÀ» °Ë»çÇÏ´Â ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç¿¡ ´ëÇÑ ÀÓ»óÀÇ¿Í È¯ÀÚµéÀÇ ÀνÄÀÌ Á¦ÇÑÀûÀÌ¾î¼ ±¤¹üÀ§ÇÑ Ã¤ÅÃÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. °Ë»ç ±âÁØÀÇ ÆíÂ÷ ¹× Àü¹® °Ë»ç ½Ã¼³¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ¹Ì°³¹ß Áö¿ª¿¡¼ÀÇ ½ÃÀå È®´ë¸¦ ´õ¿í Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ
PARP ¾ïÁ¦Á¦ÀÇ Àû¿ë ¹üÀ§¸¦ È®´ëÇÒ ¼ö ÀÖ´Â BRCA À¯ÀüÀÚ º¯ÀÌ ÀÌ¿ÜÀÇ ½Å±Ô ¹ÙÀÌ¿À¸¶Ä¿ °³¹ß¿¡´Â Å« ±âȸ°¡ Á¸ÀçÇÕ´Ï´Ù. µ¿¹ÝÁø´ÜÀ» °øµ¿ °³¹ßÇÏ´Â Á¦¾à±â¾÷°ú Áø´Ü±â¾÷ °£ÀÇ Á¦ÈÞ´Â À¯¸ÁÇÑ ¼ºÀå ¼ö´ÜÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. À¯Àüü µ¥ÀÌÅÍ ÇØ¼®¿¡ AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕÀº ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö°ú ÀÓ»óÀû ÀÇ»ç°áÁ¤À» °ÈÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ, ¿ø°ÝÀÇ·á¿Í ÀçÅà À¯ÀüÀÚ °Ë»ç Ç÷§ÆûÀÇ º¸±ÞÀÌ È®´ëµÇ¸é¼ ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç ¹× ȯÀÚ ´ë»ó ¾Æ¿ô¸®Ä¡¿¡ »õ·Î¿î ä³ÎÀÌ Á¦°øµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ½ÅÈï½ÃÀå ÁøÃâ°ú ¾×ü »ý°Ë ±â¼úÀÇ ÁøÈµµ ¹Ì°³¹ßµÈ ¼ºÀå °¡´É¼ºÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼´Â ¼¼°è PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀ» Á¶»çÇÏ¿© ¼ºÀå ÃËÁø¿äÀÎ, µ¿Çâ, ±âȸ, °úÁ¦ µî ½ÃÀå ¿ªÇп¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀå ¹üÀ§¿Í Á¤ÀÇ
½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀÎ
¼ºÀå ¾ïÁ¦¿äÀÎ
±âȸ
ÁÖ¿ä µ¿Çâ
°Å½Ã°æÁ¦ ¿äÀÎ
¼¼°èÀÇ ºÎ¹® Àü¸Á
¼¼°èÀÇ GDP ¼ºÀå Àü¸Á
COVID-19ÀÇ ¿µÇ⠺м®
¿¹Ãø¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
Á¦3Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®
Á¦Ç° ä¿ë ºÐ¼®
±ÔÁ¦ »óȲ
Porter's Five Forces ºÐ¼®
PESTLE ºÐ¼®
ÇÁ·Î¸ð¼Ç Àü·« : ÁÖ¿ä ±â¾÷º°
Á¦4Àå ¼¼°èÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð¿Í Àü³âºñ ¼ºÀå
Àý´ëÀû ¼öÀÍ ±âȸ
½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø
½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼®(2019-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø(2025-2032³â)
¼¼°èÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : Á¦Ç°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : Á¦Ç°º°(2019-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Á¦Ç°º°(2025-2032³â)
½ÃÀå ¸Å·Â ºÐ¼® : Á¦Ç°
¼¼°èÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : ¿ëµµ
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð ½ÇÀû : ¿ëµµº°(2019-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ¿ëµµº°(2025-2032³â)
½ÃÀå ¸Å·Â ºÐ¼® : ¿ëµµ
¼¼°èÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : ÃÖÁ¾»ç¿ëÀÚ
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð ½ÇÀû : ÃÖÁ¾»ç¿ëÀÚº°(2019-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2025-2032³â)
½ÃÀå ¸Å·Â ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚ
Á¦5Àå ¼¼°èÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á : Áö¿ª
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð ½ÇÀû ºÐ¼® : Áö¿ªº°(2019-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°(2025-2032³â)
ºÏ¹Ì
À¯·´
µ¿¾Æ½Ã¾Æ
³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀå ¸Å·Â ºÐ¼® : Áö¿ª
Á¦6Àå ºÏ¹ÌÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á
Á¦7Àå À¯·´ÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á
Á¦8Àå µ¿¾Æ½Ã¾ÆÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á
Á¦9Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á
Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á
Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ PARP ¾ïÁ¦Á¦ ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Àü¸Á
Á¦12Àå °æÀï ±¸µµ
½ÃÀå Á¡À¯À² ºÐ¼®(2025³â)
½ÃÀå ±¸Á¶
°æÀï °µµ ¸Ê : ½ÃÀ庰
°æÀï ´ë½Ãº¸µå
±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù ¹ßÀü)
Myriad Genetics, Inc.
Illumina, Inc.
Amoy Diagnostics Co., Ltd.
QIAGEN
Agilent Technologies, Inc.
Quest Diagnostics Incorporated
Foundation Medicine, Inc.
OncoDNA
4baseCare
AstraZeneca
Laboratory Corporation of America(R) Holdings
Genekor | MEDICAL S.A
Cambridge Bioscience Limited
BPS Bioscience, Inc.
BMG Labtech
R&D Systems, Inc(BioTechne)
BellBrook Labs
Abyntek Biopharma S.L.
Epic Sciences
Reaction Biology
Á¦13Àå ºÎ·Ï
ksm
¿µ¹® ¸ñÂ÷
Persistence Market Research has recently released a comprehensive report on the worldwide market for PARP inhibitor biomarkers. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global PARP inhibitor biomarkers market from 2025 to 2032.
Key Insights:
PARP Inhibitor Biomarkers Market Size (2025E): USD 1,035.3 Million
Projected Market Value (2032F): USD 1,833.4 Million
Global Market Growth Rate (CAGR 2025 to 2032): 8.5%
PARP Inhibitor Biomarkers Market - Report Scope:
PARP (Poly ADP-ribose polymerase) inhibitor biomarkers are crucial in identifying patients who are likely to benefit from PARP inhibitor therapies, particularly in oncology applications. These biomarkers include BRCA1/2 mutations, homologous recombination deficiency (HRD), and other DNA damage response (DDR) pathway alterations. The market caters to precision oncology practices by aiding clinicians in tailoring cancer therapies, particularly for ovarian, breast, prostate, and pancreatic cancers. As the demand for personalized medicine rises, the adoption of biomarker-driven treatment approaches is accelerating. Advancements in genomic profiling, next-generation sequencing (NGS), and companion diagnostics are significantly contributing to market growth.
Market Growth Drivers:
The global PARP inhibitor biomarkers market is driven by the rising prevalence of cancer and increasing demand for targeted therapies. As PARP inhibitors gain regulatory approval for treating multiple cancers, there is a growing need for companion diagnostic tests to identify eligible patients based on biomarker status. The increasing awareness of BRCA gene mutations and HRD as predictors of response to PARP inhibitors is boosting biomarker testing volumes. Furthermore, expanding applications of PARP inhibitors in maintenance therapy and combination treatment regimens have fueled investments in biomarker research. Government initiatives to promote precision oncology and growing investments in genomic medicine infrastructure are also propelling market growth.
Market Restraints:
Despite strong growth potential, the PARP inhibitor biomarkers market faces several limitations. High costs associated with biomarker testing and next-generation sequencing technologies pose challenges, especially in low- and middle-income regions. Reimbursement hurdles and regulatory complexities surrounding companion diagnostics can delay market entry for new tests. Additionally, limited awareness among clinicians and patients about biomarker testing for PARP inhibitor eligibility hinders broader adoption. Variability in testing standards and access to specialized laboratories further restrict market expansion in underdeveloped areas.
Market Opportunities:
Significant opportunities exist in the development of novel biomarkers beyond BRCA mutations, which can broaden the scope of PARP inhibitor applications. Collaborations between pharmaceutical companies and diagnostic firms to co-develop companion diagnostics present a promising growth avenue. The integration of artificial intelligence and machine learning in genomic data interpretation is expected to enhance biomarker discovery and clinical decision-making. Furthermore, the increasing penetration of telemedicine and at-home genetic testing platforms provides new channels for biomarker testing and patient outreach. Expansion into emerging markets and the evolution of liquid biopsy techniques also represent untapped potential for growth.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the PARP inhibitor biomarkers market globally?
Which biomarker types and cancer indications are driving the adoption of PARP inhibitor testing?
How are technological innovations influencing the competitive landscape of the PARP inhibitor biomarkers market?
Who are the key players contributing to the market, and what strategies are they using to strengthen their positions?
What are the emerging trends and future prospects in the global PARP inhibitor biomarkers market?
Competitive Intelligence and Business Strategy:
Leading players in the global PARP inhibitor biomarkers market, including Myriad Genetics, Foundation Medicine, Thermo Fisher Scientific, and Illumina, Inc., are investing heavily in innovation, strategic partnerships, and co-development of companion diagnostics. These companies are leveraging their expertise in genomic testing and bioinformatics to develop accurate and efficient biomarker assays. Collaborations with pharmaceutical companies like AstraZeneca, Merck, and GlaxoSmithKline aim to accelerate the development of companion diagnostics aligned with PARP inhibitors. Key strategies include expanding testing portfolios, enhancing NGS capabilities, and strengthening global distribution networks to capture market share in both established and emerging regions.
Key Companies Profiled:
Myriad Genetics, Inc.
Illumina, Inc.
Amoy Diagnostics Co., Ltd.
QIAGEN
Agilent Technologies, Inc.
Quest Diagnostics Incorporated
Foundation Medicine, Inc.
OncoDNA
4baseCare
AstraZeneca
Laboratory Corporation of America(R) Holdings
Genekor | MEDICAL S.A
Cambridge Bioscience Limited
BPS Bioscience, Inc.
BMG Labtech
R&D Systems, Inc (BioTechne)
BellBrook Labs
Abyntek Biopharma S.L.
Epic Sciences
Reaction Biology
PARP Inhibitor Biomarkers Market Segmentation
By Product:
BRCA 1 & 2 Testing Kits
Homologous Recombination Deficiency (HRD) Testing Kits
Homologous Recombination Repair (HRR) Testing Kits
Others
By Application:
Ovarian Cancer
Breast Cancer
Others
By End User:
Hospitals
Pharmaceutical Companies
Diagnostic Laboratories
Academic and Research Institutions
Others
By Region:
North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global PARP Inhibitor Biomarkers Market Snapshot, 2025-2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Product Adoption Analysis
3.2. Regulatory Landscape
3.3. Porter's Five Forces Analysis
3.4. PESTLE Analysis
3.5. Promotional Strategies, By Key Players
4. Global PARP Inhibitor Biomarkers Market Outlook
4.1. Key Highlights
4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
4.3. Global PARP Inhibitor Biomarkers Market Outlook: Product
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
4.3.3.1. BRCA 1 & 2 Testing Kits
4.3.3.2. Homologous Recombination Deficiency (HRD) Testing Kits
4.3.3.3. Homologous Recombination Repair (HRR) Testing Kits
4.3.3.4. Others
4.3.4. Market Attractiveness Analysis: Product
4.4. Global PARP Inhibitor Biomarkers Market Outlook: Application
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Mn), By Application, 2019-2024
4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
4.4.3.1. Ovarian Cancer
4.4.3.2. Breast Cancer
4.4.3.3. Others
4.4.4. Market Attractiveness Analysis: Application
4.5. Global PARP Inhibitor Biomarkers Market Outlook: End User
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Mn), By End User, 2019-2024
4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
4.5.3.1. Hospitals
4.5.3.2. Pharmaceutical Companies
4.5.3.3. Diagnostic Laboratories
4.5.3.4. Academic and Research Institutions
4.5.3.5. Others
4.5.4. Market Attractiveness Analysis: End User
5. Global PARP Inhibitor Biomarkers Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America PARP Inhibitor Biomarkers Market Outlook
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
6.2.1. By Country
6.2.2. By Product
6.2.3. By Application
6.2.4. By End User
6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
6.4.1. BRCA 1 & 2 Testing Kits
6.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
6.4.3. Homologous Recombination Repair (HRR) Testing Kits
6.4.4. Others
6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
6.5.1. Ovarian Cancer
6.5.2. Breast Cancer
6.5.3. Others
6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
6.6.1. Hospitals
6.6.2. Pharmaceutical Companies
6.6.3. Diagnostic Laboratories
6.6.4. Academic and Research Institutions
6.6.5. Others
6.7. Market Attractiveness Analysis
7. Europe PARP Inhibitor Biomarkers Market Outlook
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Product
7.2.3. By Application
7.2.4. By End User
7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
7.4.1. BRCA 1 & 2 Testing Kits
7.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
7.4.3. Homologous Recombination Repair (HRR) Testing Kits
7.4.4. Others
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
7.5.1. Ovarian Cancer
7.5.2. Breast Cancer
7.5.3. Others
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
7.6.1. Hospitals
7.6.2. Pharmaceutical Companies
7.6.3. Diagnostic Laboratories
7.6.4. Academic and Research Institutions
7.6.5. Others
7.7. Market Attractiveness Analysis
8. East Asia PARP Inhibitor Biomarkers Market Outlook
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Product
8.2.3. By Application
8.2.4. By End User
8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
8.4.1. BRCA 1 & 2 Testing Kits
8.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
8.4.3. Homologous Recombination Repair (HRR) Testing Kits
8.4.4. Others
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
8.5.1. Ovarian Cancer
8.5.2. Breast Cancer
8.5.3. Others
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
8.6.1. Hospitals
8.6.2. Pharmaceutical Companies
8.6.3. Diagnostic Laboratories
8.6.4. Academic and Research Institutions
8.6.5. Others
8.7. Market Attractiveness Analysis
9. South Asia & Oceania PARP Inhibitor Biomarkers Market Outlook
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Product
9.2.3. By Application
9.2.4. By End User
9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
9.4.1. BRCA 1 & 2 Testing Kits
9.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
9.4.3. Homologous Recombination Repair (HRR) Testing Kits
9.4.4. Others
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
9.5.1. Ovarian Cancer
9.5.2. Breast Cancer
9.5.3. Others
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
9.6.1. Hospitals
9.6.2. Pharmaceutical Companies
9.6.3. Diagnostic Laboratories
9.6.4. Academic and Research Institutions
9.6.5. Others
9.7. Market Attractiveness Analysis
10. Latin America PARP Inhibitor Biomarkers Market Outlook
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Product
10.2.3. By Application
10.2.4. By End User
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
10.4.1. BRCA 1 & 2 Testing Kits
10.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
10.4.3. Homologous Recombination Repair (HRR) Testing Kits
10.4.4. Others
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
10.5.1. Ovarian Cancer
10.5.2. Breast Cancer
10.5.3. Others
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
10.6.1. Hospitals
10.6.2. Pharmaceutical Companies
10.6.3. Diagnostic Laboratories
10.6.4. Academic and Research Institutions
10.6.5. Others
10.7. Market Attractiveness Analysis
11. Middle East & Africa PARP Inhibitor Biomarkers Market Outlook
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Product
11.2.3. By Application
11.2.4. By End User
11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
11.4.1. BRCA 1 & 2 Testing Kits
11.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
11.4.3. Homologous Recombination Repair (HRR) Testing Kits
11.4.4. Others
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
11.5.1. Ovarian Cancer
11.5.2. Breast Cancer
11.5.3. Others
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
11.6.1. Hospitals
11.6.2. Pharmaceutical Companies
11.6.3. Diagnostic Laboratories
11.6.4. Academic and Research Institutions
11.6.5. Others
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Myriad Genetics, Inc.
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Illumina, Inc.
12.3.3. Amoy Diagnostics Co., Ltd.
12.3.4. QIAGEN
12.3.5. Agilent Technologies, Inc.
12.3.6. Quest Diagnostics Incorporated
12.3.7. Foundation Medicine, Inc.
12.3.8. OncoDNA
12.3.9. 4baseCare
12.3.10. AstraZeneca
12.3.11. Laboratory Corporation of America(R) Holdings
12.3.12. Genekor | MEDICAL S.A
12.3.13. Cambridge Bioscience Limited
12.3.14. BPS Bioscience, Inc.
12.3.15. BMG Labtech
12.3.16. R&D Systems, Inc (BioTechne)
12.3.17. BellBrook Labs
12.3.18. Abyntek Biopharma S.L.
12.3.19. Epic Sciences
12.3.20. Reaction Biology
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations
°ü·ÃÀÚ·á